INCOG BioPharma

Executive Summary

INCOG BioPharma is a contract development and manufacturing organization (CDMO) specializing in sterile injectable drug products, serving clients from clinical through commercial stages. Headquartered in Indianapolis, Indiana, the company was founded in 2016 and is privately held. INCOG focuses on oncology and small molecules, offering end-to-end solutions including formulation development, analytical testing, and aseptic filling. With its facilities approved for commercial manufacturing, INCOG positions itself as a trusted partner for biopharmaceutical companies seeking high-quality, reliable manufacturing capacity. The CDMO market is growing, driven by increasing demand for injectable drugs and outsourcing trends, which supports INCOG's business prospects. However, as a private company, financial details and pipeline specifics are limited, making it challenging to assess valuation. Overall, INCOG represents a solid, albeit relatively opaque, player in the CDMO space with potential for steady growth through strategic partnerships and capacity expansions.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new commercial manufacturing contracts60% success
• Q4 2026Facility expansion or new aseptic filling line commissioning50% success
• Q2 2026FDA approval for additional drug product types or manufacturing lines40% success